000 02863cam a2200349 a 4500
003 EG-GiCUC
005 20250223032656.0
008 210120s2020 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.31.Ph.D.2020.Is.C
100 0 _aIslam Haney Ahmed Sami
245 1 0 _aCT perfusion for response evaluation after interventional ablation of hepatocellular carcinoma /
_cIslam Haney Ahmed Sami ; Supervised Lamiaa Ibrahim Abdelrahman , Ahmed Hosni Kamel , Mohamed Fouad Abdellatif
246 1 5 _aدور الاشعة المقطعية بخاصية النضح فى تقييم علاج أورام الكبد الاولية بالاشعة التداخلية
260 _aCairo :
_bIslam Haney Ahmed Sami ,
_c2020
300 _a192 P. :
_bcharts , facimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Radio- Diagnosis
520 _aObjective: To study the role of CT perfusion imaging technique in evaluation of hepatocellular carcinoma treatment response through monitoring changes in perfusion parameters. Methods: The study was conducted on 70 patients diagnosed with HCC, treated with loco-regional therapy between 2019 and 2020, who came for follow up to assess therapy response and to plan the next step in treatment. Imaging response was evaluated according to CT perfusion parameters. Results:Our results demonstrated that post local-treatment CTP of the recurrent tumor confirmed relative increased BFand BV and reduced MTT relative to the background values of the cirrhotic hepatic parenchyma. The recurrent HCC post-TACE shows BF=292.79±150.16, BV=15.68± 5.69 and MTT=6±2.78. The recurrent HCC post-RFA shows BF= 565.80±257.33, BV= 47.50±10.03and MTT= 7.53± 3.16. The CTP of the ablated lesions post local-treatment confirmed decreased BF and BV and increased MTTrelative to the background values of the cirrhotic hepatic parenchyma. Conclusion:CT perfusion technique showed good diagnostic performance, with high specificity and sensitivity which increased when equivocal lesions where considered as viable with lesser effect on specificity and no effect on overall accuracy. Perilesional hyperemia shouldn{u2019}t be considered as an evidence of residual viable tumor and should be differentiated from arterial phase hyperenhancement of true viable residual
530 _aIssued also as CD
653 4 _aCT Perfusion
653 4 _aHepatocellular carcinoma (HCC)
653 4 _aLoco-regional
700 0 _aAhmed Hosni Kamel ,
_eSupervisor
700 0 _aLamiaa Ibrahim Abdelrahman ,
_eSupervisor
700 0 _aMohamed Fouad Abdellatif ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c79610
_d79610